Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
62results about How to "Improve muscle function" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
"teach and repeat" method and apparatus for physiotherapeutic applications
InactiveUS20120253241A1Extended range of motionGood for healthDiagnosticsChiropractic devicesEngineeringPhysical therapy device
The present invention provides a device for controlling a physical therapy device adapted for accepting external commands, comprising:a. a moveable portion of substantially the same shape and dimensions as that portion of said physical therapy device that is adapted for interacting with at least one part of the body of a patient;b. a base;c. a motion manipulation portiond. conversion means for converting said stored time-dependent output signals to a series of command signals; and,e. means for transmitting said command signals to said physical therapy device;wherein a series of command signals are produced by the movement of said moveable portion, which, when transmitted to said physical therapy apparatus, will cause said physical therapy apparatus to undergo a series of motions substantially identical to those of said moveable portion.
Owner:HEADWAY
MAPC generation of muscle
InactiveUS8252280B1Restoring and enhancing and massTiming impairmentBiocidePeptide/protein ingredientsProgenitorMuscle tissue
The present invention relates to methods of increasing function and / or mass in damaged striated muscle tissue of interest (e.g., cardiac or muscle tissue) by providing of a population of multipotent adult progenitor cells (“MAPCs”), which effectively generate new striated muscle over time.
Owner:RGT UNIV OF MINNESOTA
Therapeutic compositions
Compositions containing ketone bodies and / or metabolic precursors thereof suitable for administration to humans and animals, which are characterized by (i) enhancing cardiac performance, especially the efficiency of the heart in utilizing glucose, (ii) providing energy, especially is to provide energy in diabetes and insulin resistance, (iii) to treat conditions caused by brain cell damage, especially by delaying or preventing brain damage in memory-related areas of the brain, such as in Alzheimer's disease and Brain damage found in brains with similar conditions. These compositions can be used as nutritional supplements, for example for athletes, or for the treatment of diseases, especially disorders related to cardiac insufficiency, insulin resistance and neuronal damage. The invention also provides methods of treatment as well as novel esters and polymers for inclusion in the compositions of the invention.
Owner:BRITISH TECH GRP LTD
Use Of A Hydroximic Acid Halide Derivative In The Treatment Of Neurodegenerative Diseases
The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl !-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
Owner:KEMPHARM DENMARK AS
Medical device comprising an artificial contractile structure
InactiveUS20120296157A1Improve the quality of lifeImprove muscle functionAnti-incontinence devicesControl devicesPower flowActuator
The present invention relates to a medical device including an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ. The medical device includes an artificial contractile structure including at least one contractile element (100) adapted to contract an organ, in such way that the contractile element (100) is in a resting or in an activated position, at least one actuator designed to activate the contractile structure, and at least one source of energy for powering the actuator. The ratio “current which is needed to maintain the contractile element in its activated position / current which is needed to change the position of the contractile element” is less than 1 / 500, preferably less than 1 / 800, and more preferably less than 1 / 1000.
Owner:MYOPOWERS MEDICAL TECH
Use of Growth Hormone Releasing Factor Analogs in Treating Patients Suffering From Wasting
ActiveUS20080167222A1Improve muscle functionQuality improvementBiocidePeptide/protein ingredientsIncreased muscle functionMuscle functions
The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.
Owner:THERATECHONOLGIES INC
Use of growth hormone releasing factor analogs in treating patients suffering from wasting
ActiveUS7893025B2Improve muscle functionQuality improvementBiocidePeptide/protein ingredientsSomatotropic hormoneIncreased muscle function
The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.
Owner:THERATECHONOLGIES INC
Propolis soft capsule and preparation method thereof
InactiveCN103637197AEasy to usePrevention and treatment of chronic complicationsOrganic active ingredientsLipidic food ingredientsDiabetes mellitusWheat germ
The invention relates to a propolis soft capsule. The propolis soft capsule comprises a rubber sheet and a capsule content, wherein the capsule content comprises the following components in percent by weight: 20%-60% of propolis supercritical CO2 extract, 30%-70% of wheat-germ oil and 1%-10% of vitamin E; components of the rubber sheet are gelatin, glycerol and purified water in a weight ratio of 100:42:100. The propolis soft capsule is integrated with improving effect of propolis on diabetes mellitus and preventing effect of vitamin E on chronic complication of the diabetes mellitus; moreover, the components are good in synergistic effect. The invention also provides a preparation method of the propolis soft capsule.
Owner:JIANGSU JIANGDAYUAN ECOLOGICAL BIOLOGICAL TECH
Methods for Treatment of Muscular Dystrophy
ActiveUS20120164151A1Improve muscle functionReduce decreaseOrganic active ingredientsMuscular disorderDystrophy fuchsMuscular dystrophy
The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.
Owner:FIBROGEN INC
Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
The invention relates to the use of a chemical substance selected from the group consisting of N-′2-hydroxy-3-(1-piperidinyl)-propoxyl 1-pyridine-1-oxide-3-carboximidoyl chloride, the optically active enantiomers and the mixtures of enantiomers thereof and pharmaceutically acceptable salts of the racemic and optically active compounds in the preparation of a pharmaceutical composition for the treatment or prevention of neurodegenerative diseases.
Owner:KEMPHARM DENMARK AS
Nutritional approach to improving athletic performance and reducing injury with l-ergothioneine and/or vitamin d2
InactiveUS20150157648A1Improve muscle functionHigh strengthBiocideOrganic active ingredientsNutritional approachesAntioxidant
Nutritional products, compositions, functional ingredients, medical foods, pharmaceutical preparations and methods of use are disclosed for support and improvement of athletic performance (strength, flexibility, endurance, balance, and conditioning), and prevention and repair of injuries, including improving or maintaining muscle mitochondrial health, stimulating muscle mitochondrial biogenesis as well as other indications as set forth herein. In addition, pharmaceutical, nutraceutical and nutritional medical food compositions that are useful in conditions, normal or abnormal, associated with mitochondrial dysfunction and altered biogenesis in organ systems consisting of skeletal muscle, smooth muscle and cardiac muscle are also disclosed. L-Ergothioneine (also referred to as Ergothioneine or ET), Vitamin D2 (Ergocalciferol) and / or other antioxidants are disclosed for use in pharmaceutical, nutraceutical and nutritional medical food compositions for uses to stimulate production of bioactive molecules, including but not limited to glutathione, alpha synuclein, and IL-6.
Owner:ENTIA BIOSCI
Compositions and methods for treatment of mitochondrial diseases
InactiveUS20010016576A1Minimize consequencesInhibiting consequenceBiocideSenses disorderDiseaseMitochondrial disease
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts sufficient to treat symptoms resulting from mitochondrial respiratory chain deficiencies.
Owner:WELLSTAT THERAPEUTICS
Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
ActiveUS9499817B2Inhibit progressImprove muscle functionSplicing alterationSugar derivativesDiseaseNucleotide
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy. One aspect the disclosure provides an isolated antisense polynucleotide wherein the polynucleotide specifically hybridizes to an exon target region of a gamma sarcoglycan RNA, wherein the exon is selected from the group consisting of exon 4 (SEQ ID NO:1), exon 5 (SEQ ID NO: 2), exon 6 (SEQ ID NO: 3), exon 7 (SEQ ID NO: 4) and a combination thereof. In some embodiments, the antisense polynucleotide cannot form an RNase H substrate, and in further embodiments the antisense polynucleotide comprises a modified polynucleotide backbone.
Owner:UNIVERSITY OF CHICAGO
Methods for treatment of muscular dystrophy
ActiveUS8771692B2Improve muscle functionReduce decreaseMuscular disorderImmunoglobulins against growth factorsDuchenne muscular dystrophyMuscular dystrophy
Owner:FIBROGEN INC
Compositions comprising urolithin compounds
ActiveUS10695320B2Improve bioavailabilityImproved profileOrganic chemistryMuscular disorderDietary supplementUrolithin
The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and / or prophylaxis of a muscle-related pathological condition.
Owner:AMAZENTIS
Chair (variants)
InactiveUS8118366B2Reduce hypodynamiaEasy to useOperating chairsDental chairsEngineeringShock absorber
The device is embodied in four variants. The home chair comprises a three-dimensional frame with a seat pivotally connected thereto in such a way that it is tiltable forward and up-and-down, a seat arresting device, a smooth displacement compensator, a reset mechanism embodied in the form of an oil-gas damper and a backrest, the tilt angle with respect to the seat is less than 90° and the distance between the top edge and the seat is less than 250 mm. The school variant is provided with a smooth displacement compensator and a reset mechanism embodied in the form of a spring. The child variant is adjustable in the vertical and horizontal planes, thereby making it possible to select the optimal sitting parameters of a child during the growth thereof, and comprises a seat provided with a tilt angle adjusting unit, a smooth displacement compensator and a reset mechanism.
Owner:MATVEEV KIRILL VLADIMIROVICH
Systems and methods for enhancing function of spine stabilization muscles associated with a spine surgery intervention
ActiveUS11331488B2Promote recoveryEnhance neural control and functionSpinal electrodesMagnetotherapy using coils/electromagnetsSpinal columnNeuromuscular control
Owner:MAINSTAY MEDICAL
Medical device comprising an artificial contractile structure
InactiveCN103037803AImprove muscle functionImprove the quality of lifeAnti-incontinence devicesControl devicesBiologyMechanical engineering
The present invention relates to a medical device comprising an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ. Said medical device comprises an artificial contractile structure comprising at least one contractile element (100) adapted to contract an organ, in such way that said contractile element (100) is in a resting or in an activated position, at least one actuator designed to activate said contractile structure, and at least one source of energy for powering said actuator. The ratio 'current which is needed to maintain the contractile element in its activated position / current which is needed to change the position of the contractile element' is less than 1 / 500, preferably less than 1 / 800, and more preferably less than 1 / 1000.
Owner:MYOPOWERS MEDICAL TECH
Compositions and Methods for Muscle Regeneration Using Prostaglandin E2
ActiveUS20170252354A1Growing populationImprove muscle functionOrganic active ingredientsMuscular disorderDiseasePhysical medicine and rehabilitation
Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and / or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Use of myostatin inhibitors and combination therapies
ActiveUS10946036B2Maximizing and improving benefitEnhance and optimize efficacyOrganic active ingredientsMuscular disorderMyostatinNeurophysins
Owner:SCHOLAR ROCK INC
Chair (variants)
InactiveUS20100176637A1Reduce hypodynamiaEasy to useOperating chairsDental chairsEngineeringShock absorber
The device is embodied in four variants. The home chair comprises a three-dimensional frame with a seat pivotally connected thereto in such a way that it is tiltable forward and up-and-down, a seat arresting device, a smooth displacement compensator, a reset mechanism embodied in the form of an oil-gas damper and a backrest, the tilt angle with respect to the seat is less than 90° and the distance between the top edge and the seat is less than 250 mm. The school variant is provided with a smooth displacement compensator and a reset mechanism embodied in the form of a spring. The child variant is adjustable in the vertical and horizontal planes, thereby making it possible to select the optimal sitting parameters of a child during the growth thereof, and comprises a seat provided with a tilt angle adjusting unit, a smooth displacement compensator and a reset mechanism.
Owner:MATVEEV KIRILL VLADIMIROVICH
Compositions and methods for muscle regeneration using prostaglandin E2
ActiveUS9918994B2Growing populationImprove muscle functionOrganic active ingredientsMuscular disorderDiseaseE2 prostaglandin
Provided herein are compositions, methods, and kits for proliferating muscle cells by exposing the muscle cells to a prostaglandin E2 (PGE2) compound or compound that activates PGE2 signaling. Also provided are methods for regenerating muscle in a subject suffering from muscular atrophy, dystrophy, and / or injury by administering a PGE2 compound alone or in combination with isolated muscle cells. The PGE2 compound in combination with the isolated muscle cells can be administered prophylactically to prevent a muscle disease or condition.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV
Compositions and methods for treating and preventing muscular disorders and dystrophies, steroid side effects, and inflammation
PendingUS20210198669A1Improve the level ofImprove muscle functionOrganic active ingredientsMuscular disorderDiseaseAntisense RNA
The present disclosure relates to compositions comprising an antisense RNA sequence comprising a region of complementarity that is substantially complementary to an miRNA. Pharmaceutical compositions comprising the antisense RNA molecule, optionally further comprising an anti-inflammatory corticosteroid are also disclosed. Methods of treating or preventing inflammation, a steroid side effect, or a muscle disease using the one or the pharmaceutical compositions are also disclosed.
Owner:U S ARMY MEDICAL RES ACQUISITION ACTIVITY
Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
Owner:KEMPHARM DENMARK AS
Composition for alleviating, preventing or treating sarcopenia, containing whey protein hydrolysate as active ingredient
PendingUS20220322700A1Induce muscle hypertrophyImprove muscle functionHydrolysed protein ingredientsMuscular disorderBacillus licheniformisHydrolysate
The present disclosure relates to a composition for alleviating, preventing or treating sarcopenia, containing, as an active ingredient, a whey protein hydrolysate, obtained by performing, on whey protein, primary hydrolysis using a Bacillus licheniformis-derived endoprotease and secondary hydrolysis using an Aspergillus oryzae-derived exoprotease, which inhibits protein degradation and activates protein synthesis through the PI3K-Akt pathway, thereby reducing muscle loss and increasing muscle size and muscle strength.
Owner:NEO CREMAR CO LTD
Therapeutic uses and methods
PendingUS20200095587A1Increase delayImprove muscle performanceOrganic active ingredientsGenetic material ingredientsDiseaseMuscular dystrophy
The specification discloses a method of treating muscular disorders such as muscular dystrophy comprising periodically administering an inhibitory oligonucleotide to human CD49d ((the alpha 4 chain of VLA-4).
Owner:ANTISENSE THERAPEUTICS LTD
Medical device comprising an artificial contractile structure
ActiveUS9717579B2Reduce corrosionImprove the quality of lifeHeart valvesAnti-incontinence devicesActuatorMedical device
A medical device includes an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ, an artificial contractile structure including at least one contractile element (100) adapted to contract an organ, in such way that the contractile element (100) is in a resting or in an activated position, at least one actuator designed to activate the contractile structure, and at least one source of energy for powering the actuator. The ratio “current which is needed to maintain the contractile element in its activated position and in its resting position / current which is needed to change the position of the contractile element” is less than 1 / 500, preferably less than 1 / 800, and more preferably less than 1 / 1000. The medical device further includes elements for reducing corrosion of the medical device.
Owner:MYOPOWERS MEDICAL TECH FRANCE SAS
Composition for promoting skeletal muscle activity via induction of mitochondrial biogenesis comprising of azelaic acid as an active ingredient
InactiveUS20190328694A1Increasing mitochondrial densityImprove muscle functionMuscular disorderNeuromuscular disorderDiseaseSide effect
The present invention relates to a composition for promoting mitochondrial biogenesis, which includes azelaic acid as an active ingredient. It was confirmed that azelaic acid is a compound mainly contained in cereals and natural products and has the advantage of no or little side effects, and mitochondrial autophagy and mitochondrial DNA synthesis in cells are induced, thereby ultimately having activity of increasing mitochondrial density. Therefore, azelaic acid can be used for the treatment of mitochondrial dysfunction-associated disease by the failure of homeostasis control of the mitochondria, for example, mitochondrial activity or the decrease in the number of mitochondria. In addition, azelaic acid can be provided to reinforce a muscle function and prevent muscle aging using the activity, and to be effectively used in food material, a pharmaceutical composition, and health functional foods for treating mitochondrial dysfunction-associated disease, reinforcing a muscle function, or preventing muscle aging.
Owner:KOREA UNIV RES & BUSINESS FOUND
Medical device comprising an artificial contractile structure
ActiveUS20170290649A1Improving sphincter muscle functionImprove the quality of lifeAnti-incontinence devicesControl devicesFunctional disturbanceActuator
A medical device including an artificial contractile structure which may be advantageously used to assist the functioning of a hollow organ. Specifically, the medical device includes an artificial contractile structure with at least one contractile element adapted to contract an organ, in such way that the contractile element is in a resting or in an activated position, at least one actuator designed to activate the contractile structure, and at least one source of energy for powering the actuator. The medical device also includes a means for reducing corrosion of the medical device hence reducing the risk of the device dysfunction and patient contamination.
Owner:MYOPOWERS MEDICAL TECH FRANCE SAS
A highly concentrated seawater mineral extract and uses thereof
ActiveUS20180177714A1Reduce stroke morbidityReduce mortalityCosmetic preparationsHeavy metal active ingredientsSalt contentBrix
Owner:ORIEL SEASALT COMPANY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com